Clinical trial NCT00005641 (phase 2, status: terminated)
Conditions: chronic myeloproliferative disorders, graft versus host disease, leukemia, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes
ICD codes: D47.1, D89.810, D89.811, D89.813, D89.812, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C96.20, C96.29, D47.09, D46.9, D46.C, D46.Z
Drugs: busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone
SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Reason stopped: 
    low study accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed malignancy Acute myeloid leukemia (AML)
        Complete remission 1 (CR1): high risk defined by poor cytogenetics (e.g., deletions,
        additions, or multiple abnormalities) Complete remission 2 (CR2) Induction failures
        Relapse: at least one reinduction attempt if at least 10% marrow blasts Acute lymphocytic
        leukemia CR1: high risk defined by overt CNS involvement or poor cytogenetics (e.g.,
        additions, deletions, translocations, or multiple abnormalities) CR2 Induction failures
        Relapse as for AML Chronic myelogenous leukemia Chronic phase (CP) 1 Accelerated phase
        (AP)/CP2: blast phase patients require induction and achievement of a second chronic phase
        prior to transplantation Chronic lymphocytic leukemia Relapse: any stage and must have
        received no greater than 3 regimens since diagnosis Multiple myeloma Primary refractory
        disease at diagnosis Relapse (no greater than 2): sensitive disease Plasma cell leukemia
        Inability to achieve a complete remission or relapse after autologous transplantation (no
        greater than 40 years) Myelodysplasia All FAB subtypes Myeloproliferative disorders Poor
        response to medical therapy OR Cytogenetic abnormalities Severe aplastic anemia (SAA) (for
        unrelated and/or mismatched donors) Very SAA at diagnosis OR SAA: induction failures One
        antigen mismatch (recipient age 15 to 55) Related donors may be A, B, or DR mismatched
        Unrelated donors may be A or B mismatched (DRB1 match) Phenotypic (6 out of 6) match
        Recipient age 51 to 60 if related donor Recipient age 41 to 55 if unrelated donor

        PATIENT CHARACTERISTICS: Age: 15 to 60 Performance status: ECOG 0-1 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL
        SGOT/SGPT no greater than 3 times normal PT/PTT normal Renal: Creatinine no greater than
        2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: LVEF at least 45% by MUGA
        scan or echocardiography Greater than 6 months since myocardial infarction No uncontrolled
        arrhythmias Pulmonary: FEV1 and DCLO at least 50% predicted Other: No psychosocial
        conditions that would preclude study No uncontrolled diabetes mellitus No uncontrolled
        thyroid disease No active serious infections HIV negative Not pregnant or nursing Negative
        pregnancy test

        PRIOR CONCURRENT THERAPY: See Disease Characteristics